ASTRO Offers Guidance on RT for IDH-Mutant Diffuse Grade 2, 3 Glioma
Guideline recommendations support reduction in volume of brain irradiation while attempting to maximize disease control.
Guideline recommendations support reduction in volume of brain irradiation while attempting to maximize disease control.
Treatment of fatigue related to high-grade glioma using armodafinil did not show a meaningful benefit over placebo in a phase 3 trial.
he designation is supported by data from a phase 1 trial conducted by Reata Pharmaceuticals in 2016. Findings from the study showed 44% of patients treated with berubicin (n=11 out of 25) experienced a statistically significant improvement in progression free survival.
[OncoTargets and Therapy] A meta-analysis was conducted to evaluate the effect of abnormal EGFR expression on overall survival (OS) in patients with glioma.
[OncoTargets and Therapy] This research examines overall risks of all-grade and high-grade diarrhea during vandetanib treatment, to gain a better understanding of its prediction and management.
The 2016 WHO Classification of Infiltrating Gliomas alters diagnostic criteria, providing the basis for clinical trial inclusion or exclusion based on an integrated diagnosis and setting the stage for all future research, according to a summary of 4 posters related to CNS biomarkers presented at the ASCO 2016 Annual Meeting.
The addition of chemotherapy to radiation therapy prolonged survival in adults with grade 2 glial brain tumors.
Adding panobinostat to radiotherapy appears safe, tolerable, and has preliminary efficacy for treating recurrent high-grade gliomas.
This technique, which does not use pharmaceutical sedatives, can ease the perioperative discomfort and anxiety experienced by some patients undergoing fully awake craniotomy to remove glioma.
Detailed new information about diffuse glioma has come from an international collaborative study, raising hopes for improved clinical outcomes from a better understanding of the disease.